BRAF+ melanoma
What makes it different, makes it vulnerable

BRAF inhibitors

Targeting the MAP kinase pathway

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), for patients with resectable cutaneous melanoma and a confirmed BRAF V600 mutation, a certain targeted therapy can be given as adjuvant therapy after complete resection to reduce the risk that the tumour will return.1,2 New adjuvant therapies are available,3 including targeted agents,4 which work directly on the oncogenic driver by targeting the MAP kinase pathway, through BRAF or MEK inhibition,5,6 and immunotherapies.7,8

For patients with unresectable or metastatic cutaneous melanoma and a confirmed BRAF V600 mutation, there are currently several licensed treatment options available, including targeted agents.3,9,10

BRAF and MEK inhibition target the MAP kinase pathway5,6

 

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cutaneous Melanoma. V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 21, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. National Cancer Institute. NCI Dictionary of Cancer Terms. http://www.cancer.gov/publications/dictionaries/cancerterms. Accessed August 28, 2019.
  3. Michielin O, et al; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Sept 30 [Epub ahead of print]. https://www.esmo.org/Guidelines/Melanoma/Cutaneous-Melanoma. Accessed October 16, 2019.
  4. Targeted Oncology. Europe approves adjuvant dabrafenib/trametinib for BRAF+ melanoma [press release]. August 30, 2018. https://www.targetedonc.com/news/europe-approves-adjuvant-dabrafenibtrametinib-for-braf-melanoma. Accessed September 19, 2019.
  5. Inamdar GS, et al. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80(5):624-37.
  6. Paluncic J, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863(4):770-84.
  7. MarketWatch. European commission approval Bristol-Myers Squibb’s Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection [press release]. July 31, 2018. https://www.marketwatch.com/press-release/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumabfor-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection-2018-07-31. Accessed September 19, 2019.
  8. OncLive. Adjuvant pembrolizumab approved in EU for state III melanoma [press release]. December 17, 2018. https://www.onclive.com/web-exclusives/adjuvant-pembrolizumab-approved-in-eu-for-stage-iii-melanoma. Accessed September 19, 2019.
  9. OncLive. Binimetinib/encorafenib combo approved in Europe for BRAF+ melanoma [press release]. September 20, 2018. https://www.onclive.com/web-exclusives/binimetinibencorafenib-combo-approved-in-europe-for-braf-melanoma. Accessed September 19, 2019.
  10. OncLive. Dabrafenib/trametinib combo granted EU approval for advanced melanoma [press release]. September 1, 2015. https://www.onclive.com/web-exclusives/dabrafenibtrametinib-combo-granted-eu-approval-for-advanced-melanoma. Accessed September 19, 2019.